What Is FDG Uptake? Does It Mean Cancer?

ContributorsProf. Dr. Mustafa ÖzdoğanAuthor

PublishedMar 13, 2023

UpdatedOct 20, 2026

15 min read

What Is FDG Uptake? Does It Mean Cancer?

In this article

FDG uptake is one of the most common and worrying phrases in PET-CT reports. A patient reading "FDG uptake observed" or "SUVmax 6.2" often immediately thinks of cancer. But that assumption is incorrect: FDG uptake indicates cellular energy consumption, not cancer —and cancer is not the only process that uses energy rapidly. Inflammation, infection, a healing wound and even brown fat activated by feeling cold can all show uptake.

What Is FDG Uptake?

FDG uptake is a term used in positron emission tomography (PET) imaging. FDG, short for FluoroDeoxyGlucose, is a radiolabeled sugar molecule.

How Does It Work? To cells, FDG is indistinguishable from normal sugar, or glucose. They take it up as sugar. Because its structure is slightly modified, however, cells cannot break it down —so it becomes trapped and accumulates inside them. PET shows this accumulation. What the scanner sees is not the tumor itself, but which cells consume how much sugar.

Cancer cells divide and grow rapidly, requiring much more energy, or sugar, than normal cells. This is called the Warburg effect . FDG therefore accumulates in cancerous tissue, appearing as a bright focus on PET.

The Most Important Sentence in This Article FDG uptake does not mean "cancer is present"; it means "cells here are consuming sugar rapidly." Cancer is a major cause, but not the only one. Understanding this distinction is essential to interpreting a PET report correctly.

Planning the scan, preparing the radiopharmaceutical, operating the scanner and interpreting results are the responsibility of a nuclear medicine specialist . The treating physician assesses the report together with the clinical picture and other imaging findings.

Does FDG Uptake Mean Cancer?

No— it does not establish a cancer diagnosis on its own. FDG uptake is a finding, not a diagnosis . Cancer cells show intense uptake, but not everything with intense uptake is cancer.

What Is a False Positive? When a bright PET focus is not cancer, it is called a false positive . This is a natural consequence of how PET works, rather than a defect. A final decision about a suspicious focus therefore almost always depends on biopsy . The reasoning "it showed uptake on PET, so it must be cancer" is wrong and may cause unnecessary treatment.

Noncancerous Causes of FDG Uptake

Condition	Examples and Notes
Infections	Bacterial, fungal and viral infections; abscesses; tuberculosis. Uptake may be intense.
Inflammatory Conditions	Rheumatoid arthritis, spondyloarthropathies, vasculitis, thyroiditis
Granulomatous Diseases	Sarcoidosis, tuberculosis, histoplasmosis. Sarcoidosis in lymph nodes can closely mimic cancer metastases.
Trauma and Surgery	Surgical sites, biopsy sites, healing fractures and drain tracts may show uptake for weeks
Brown Fat	Symmetrical uptake around the neck, shoulders and spine. Very common in cold conditions and in young, slim individuals. The most common benign finding that may be mistaken for metastasis.
Muscle Activity	Exercise before scanning, talking or chewing gum during the scan (vocal cords and chewing muscles), tension
Medications	Bone marrow stimulants (G-CSF) cause diffuse marrow and splenic uptake; metformin causes intense bowel uptake; corticosteroids may suppress uptake
After Vaccination	Uptake in the vaccinated arm and same-side axillary nodes, a particularly common interpretive pitfall in recent years
Neurological and Muscle Conditions	Inflammatory muscle conditions such as myositis; some neurological disorders

Physiological (Normal) Uptake Some organs always take up FDG even when healthy. This is normal: the brain (which runs on glucose and has the highest uptake), heart muscle, kidneys, urinary tract and bladder (FDG is excreted in urine), liver and spleen (moderate uptake), bowel and the thymus in young people. Experienced nuclear medicine specialists can readily distinguish these patterns.

What Does SUV Mean?

SUV (standardized uptake value) numerically measures the intensity of tissue FDG uptake. Simply put, it is the ratio of radioactivity accumulating in an area to the total administered activity per kilogram of body weight.

Tumor parameters assessed with FDG PET: SUVmax, SUVmean, MTV and TLG — Tumor parameters assessed with FDG-PET: SUVmax, SUVmean and derived volumetric measures.

Parameter	What Does It Measure?	Clinical Role
SUVmax	The highest single-point value in the lesion, representing the most active tumor area	The most commonly used parameter and the one emphasized in reports. Easy to measure, with good reproducibility.
SUVmean	All values within the lesion, expressed as their average	Reflects overall tumor activity; more variable because it depends on how boundaries are drawn.
MTV (metabolic tumor volume)	Tissue above a specified uptake threshold, measured by its volume	Indicates tumor burden; used in research and some lymphoma protocols.
TLG (total lesion glycolysis)	SUVmean × MTV: a combination of volume and intensity	Measures total metabolic burden. Prognostic value has been demonstrated, but it is less widely used than SUVmax in routine practice.

Above What SUV Is Cancer Suspected?

A commonly used threshold is 2.5. However, this number has important limitations and is not decisive on its own.

Problems with the "SUV 2.5" Rule

It Varies Between Scanners. Different PET scanners, reconstruction algorithms and centers may produce different SUVs for the same lesion. Therefore, follow-up scans should be performed at the same center when possible.
It Depends on Timing. The longer the interval after FDG injection, generally 60 minutes, the more tumor SUV continues to rise.
Blood Glucose Affects It. High blood glucose competes with FDG and reduces tumor uptake, potentially causing a false negative.
It Depends on Lesion Size. In lesions smaller than approximately 8-10 mm , the partial-volume effect causes SUV to be underestimated. A small nodule's low SUV does not prove it is benign.
Inflammation Can Easily Exceed 2.5. Active infection or sarcoidosis can produce SUVmax values of 8-10.

The Correct Approach SUV is interpreted alongside three things, not alone : (1) the lesion's CT appearance and location, (2) clinical history and previous imaging, and (3), when necessary, biopsy. During follow-up, the direction of change matters more than the absolute number: a decrease from 9 to 3 is more meaningful than the value 3 alone.

Which Cancers Show FDG Uptake, and Which May Not?

This distinction is important because it determines when PET is useful.

Cancers with Intense FDG Uptake

Cancers That May Show Low FDG Uptake

Lung Cancer (non-small cell and small cell)
Lymphomas especially Hodgkin and aggressive B-cell lymphomas
Colorectal Cancer
Esophageal Cancer
Head and Neck Cancers
Melanoma
Pancreatic Cancer
Breast Cancer ductal type
High-Grade Sarcomas

Lobular Breast Cancer often invisible on PET because of its diffuse, single-file growth
Mucinous (mucus-producing) tumors of the stomach, colon and ovary
Well-Differentiated Neuroendocrine Tumors for which Gallium-68 DOTATATE is used
Prostate Cancer usually low uptake; PSMA-PET is preferred
Hepatocellular Carcinoma especially well-differentiated tumors
Renal Cell Carcinoma: Variable
Low-Grade Lymphomas
Some Low-Grade Brain Tumors
Mesothelioma: Variable

A Common Mistake "The PET was clear, so there is no cancer" is not always a valid conclusion. Normal PET findings do not exclude the cancers in the right-hand column above. For example, lobular breast cancer may remain PET-silent despite extensive metastases; CT and MRI are more reliable in these patients. Similarly, peritoneal spread in thin layers may escape detection.

Why Is FDG-PET Less Effective in the Brain and Liver?

These organs share a particular problem: background noise.

BrainBrain tissue obtains almost all its energy from glucose and has the highest FDG uptake of any organ. Identifying a tumor against this bright background is like searching for stars while looking at the sun.

LiverNormal liver tissue also shows moderate, heterogeneous uptake. Small or low-grade lesions can disappear into this background.

The SolutionFor both organs, magnetic resonance imaging (MRI) is clearly superior. Contrast-enhanced MRI is standard for both liver and brain imaging.

What Are PET-CT and PET-MRI?

PET-CT combines positron emission tomography and computed tomography in one scanner. The principle is simple: PET identifies activity but shows anatomy poorly; CT shows anatomy well but cannot show that activity. Overlaying them identifies exactly which organ or lymph node contains a bright focus. Today, when someone says they had a PET scan, they almost always mean PET-CT.

PET-MRI combines PET with magnetic resonance imaging. It distinguishes soft tissues much better than CT and has a substantially lower ionizing radiation dose , making it advantageous for children and young people needing repeated scans. It offers advantages in the brain, liver, pelvis, and head and neck. However, scanners are less available, scans take longer, and it is inferior to CT for the lungs.

About Radiation Dose Total radiation exposure from FDG PET-CT varies with the CT protocol but is generally 10-25 mSv , equivalent to several years of natural background exposure. For cancer diagnosis and staging, this is an acceptable trade-off. It is also why unnecessary PET scans without an indication should be avoided. PET is not a screening or check-up test for healthy people.

Preparing for PET: A Direct Effect on Results

PET is particularly sensitive to patient preparation. Failing to follow these rules may require a repeat scan or lead to misinterpretation.

Rule	Reason
Fast for 4-6 hours before scanning	Eating increases glucose and insulin; insulin directs FDG into muscle and fat, away from the tumor. Only water is allowed.
Blood glucose is checked	High glucose competes with FDG and reduces tumor uptake. Scans are generally postponed above 150-200 mg/dL. Patients with diabetes must discuss medication and insulin timing with the center.
Avoid strenuous exercise for 24 hours	Active muscle takes up FDG, creating diffuse and confusing uptake.
Stay warm and avoid feeling cold	Cold activates brown fat, producing symmetrical neck and shoulder uptake that can mimic metastases. This is why waiting rooms are kept warm before scanning.
Do not talk or chew gum while waiting	The vocal cords and chewing muscles take up FDG.
Drink plenty of water and urinate immediately before scanning	FDG is excreted in urine; intense bladder activity can obscure pelvic lesions.
Report your medications	Particularly important are metformin (which causes intense bowel uptake and may temporarily be withheld on medical advice when abdominal assessment is needed), corticosteroids and bone marrow-stimulating injections .
Report recent procedures	Dates of surgery, biopsy, vaccination and radiotherapy directly affect interpretation.

When Should PET Be Performed After Treatment? An early scan can mistake healing-related inflammation for disease. Generally recommended waiting intervals are: at least 2-3 weeks after chemotherapy (preferably toward the end of a cycle), 4-6 weeks after surgery, at least 8-12 weeks after radiotherapy . Inflammatory uptake within the radiation field can persist for months.

PET for Assessing Treatment Response

This may be its most valuable role. When a tumor responds to chemotherapy, metabolic activity falls before its size decreases —allowing PET to detect response weeks before CT can. PET also helps determine whether a residual mass is viable tumor or dead scar tissue when CT cannot.

PET-CT: The Most Effective Imaging Method for Measuring Treatment Response — Our patient had left breast cancer with left axillary and mediastinal nodal spread, assessed as stage 4. After an excellent chemotherapy response, widespread new active nodes appeared during follow-up. PET-CT suggested a **"sarcoid reaction"** , a benign immune response rather than recurrent cancer; biopsy confirmed it. *(Image reference: Prof. Dr. Akın Yıldız)*

Why Is This Case So Instructive? New active nodes could initially have suggested progression and prompted a treatment change. In fact, the finding was a benign immune response. This illustrates the article's opening principle in practice: uptake is a finding; diagnosis is established by biopsy. Sarcoid-like reactions are more common in patients receiving immunotherapy (Türkçe) .

The Deauville Scale in Lymphoma PET has a particularly strong role in lymphoma, where response is assessed not by SUV alone but with the 5-point Deauville scale , comparing lesion uptake with the liver and mediastinal blood pool . Scores 1-3 indicate response and 4-5 inadequate response. Adjusting treatment intensity according to interim PET is now a standard part of lymphoma management.

A Special Issue in Immunotherapy: Pseudoprogression Even when immunotherapy is working, intense immune-cell infiltration may make lesions temporarily larger and brighter. This is called pseudoprogression , or apparent progression. A single PET scan during immunotherapy therefore does not determine that disease has progressed; clinical findings and repeat imaging are assessed together.

PET Radiopharmaceuticals Other Than FDG

FDG is the most common PET tracer, but not the only one. In some cancers, imaging focuses not on the tumor's sugar consumption but on a specific target on its surface , providing much greater sensitivity.

Gallium-68 DOTATATE: Neuroendocrine Tumors

Gallium-68 DOTATATE PET-CT for optimal assessment of pancreatic neuroendocrine cancer — Pancreatic neuroendocrine cancer of the well-differentiated type is best assessed using Gallium-68 DOTATATE PET-CT. In this patient, gallium PET showed local invasion rendering the tumor inoperable but no distant spread. An excellent response followed three cycles of intravascular (intra-arterial) lutetium treatment. *(Image reference: Prof. Dr. Akın Yıldız)*

Well-differentiated neuroendocrine tumors grow slowly and have low FDG uptake , so conventional PET can be misleading. In contrast, their surfaces contain abundant somatostatin receptors , which DOTATATE binds specifically.

Imaging and Treatment Sharing a Target: Theranostics This is DOTATATE PET's real strength. If a tumor shows uptake, radionuclide treatment targeting the same structure can be given using Lutetium-177 DOTATATE . Imaging is therefore also a test of treatment eligibility. This is called theranostics (therapy + diagnostics), the fastest-growing field in nuclear medicine.

Gallium-68/F-18 PSMA: Prostate Cancer

PSMA PET-CT showing bone metastases in prostate cancer — PSMA PET-CT images of bone metastases in prostate cancer. *(Image reference: Prof. Dr. Akın Yıldız)*

PSMA (prostate-specific membrane antigen) is present in normal prostate tissue, but in prostate cancer cells it is much more abundant . By targeting this protein, PSMA-PET detects prostate cancer cells with high sensitivity.

Why Has PSMA-PET Become So Important? Prostate cancer generally shows low FDG uptake, limiting conventional PET. PSMA-PET can detect small metastases missed by bone scintigraphy or CT. It is particularly valuable in patients with rising PSA after surgery or radiotherapy whose disease cannot be located . Localization often directly changes treatment. Theranostics also applies: patients with PSMA uptake may receive Lutetium-177 PSMA treatment.

FAPI PET

FAPI (fibroblast activation protein inhibitor) PET targets activated fibroblasts around the tumor rather than cancer cells themselves. Tumors reprogram their supporting tissue, causing these cells to produce large amounts of FAP.

FAPI has two advantages over FDG: no fasting is required and background uptake in normal tissues is very low , particularly in the brain, liver and gastrointestinal tract. It is therefore promising where FDG is less effective: liver, pancreatic, gastric and biliary cancers and peritoneal spread. For most indications it remains investigational and has not entered routine use.

PET Tracer	Target	Principal Uses
F-18 FDG	Sugar (glucose) metabolism	Lung, lymphoma, colorectal, esophageal, head and neck, melanoma: the most widely used tracer
Ga-68 DOTATATE	Somatostatin receptors	Well-differentiated neuroendocrine tumors; eligibility for Lu-177 treatment
Ga-68/F-18 PSMA	Prostate-specific membrane antigen	Prostate cancer staging, localization when PSA rises, Lu-177 PSMA eligibility
FAPI	Activated fibroblasts surrounding the tumor	Liver, pancreatic, gastric and biliary cancers; peritoneal spread (largely investigational)
F-18 NaF	Bone formation activity	Bone metastases

Frequently Asked Questions

My Report Says "FDG Uptake Observed." Do I Have Cancer?: No. This alone does not diagnose cancer. Inflammation, infection, previous surgery, vaccination or brown fat may also cause uptake. Diagnosis requires the lesion's location and appearance, clinical history and often biopsy . Your treating physician should interpret the report.
My SUVmax Is 6. Is That High?: It means nothing in isolation. The same number can occur in a healing surgical wound, active infection or tumor. SUV varies with the scanner, timing, blood glucose and lesion size. What matters is interpreting the finding in its full context, not the number alone.
Does a Clear PET Mean I Do Not Have Cancer?: It is often reassuring but not a guarantee. Lobular breast cancer, mucinous tumors, well-differentiated neuroendocrine tumors, prostate cancer and some liver tumors may be PET-silent. In addition, lesions smaller than 8-10 mm may be missed because they are near the scanner's resolution limit.
Can I Have My Follow-Up PET at a Different Center?: If possible, using the same center is preferable. Different scanners and processing methods may produce different SUVs for the same lesion, making it difficult to determine whether uptake increased or decreased.
Is PET Harmful? Can I Have It as a Check-Up?: A PET-CT delivers approximately 10-25 mSv. This is acceptable for cancer diagnosis, staging and follow-up. However, PET is not used to screen healthy people because of unnecessary radiation and the risks of unnecessary biopsies and anxiety from false positives.
I Have Diabetes. Can I Undergo PET?: Yes, but preparation requires more care. Glucose must be within the target range during scanning, and medication/insulin timing must be discussed with the center. Also report if you take metformin , which causes intense bowel uptake and may hinder abdominal assessment.
Can I Have PET Immediately After Surgery or Radiotherapy?: Generally not. Healing-related inflammation causes intense uptake that may be mistaken for disease. After surgery, a rough waiting interval of 4-6 weeks is recommended, compared with 8-12 weeks after radiotherapy. Your physician determines the correct timing.

In Summary FDG-PET is among our strongest tools for cancer staging, treatment-response assessment and recurrence investigation. However, it images metabolic activity, not cancer itself. Not every bright focus is cancer, and not every PET-silent finding proves the absence of cancer. Reported numbers gain meaning when the requesting physician considers the clinical picture, other imaging and biopsy when needed.

Sources

1. Zhu, A., Lee, D., Shim, H., & Li, Q.. Positron emission tomography (PET) imaging in cancer detection and therapy: A review. Accounts of Chemical Research, 2020.

2. M Weineisen, M Schottelius, J Simecek, RP Baum, Akın Yıldız, et al. 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. Journal of Nuclear Medicine, 2015

3. Czernin, J., Allen-Auerbach, M., & Schelbert, H. R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. Journal of Nuclear Medicine 2007

Reader comments

Share your comment

Your name and comment are published only after administrator approval. Your email address is never shown to visitors.

Be the first to comment.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

Menu

What Is FDG Uptake? Does It Mean Cancer?

What Is FDG Uptake?